RecruitingPhase 4NCT06333145

ED90 of Remimazolam Anesthesia Induction in Drug-induced Sleep Endoscopy in Adults

The 90% Effective Dose (ED90) of Remimazolam Anesthesia Induction in Drug-induced Sleep Endoscope in Adult: an up and Down Sequential Trial


Sponsor

Tongji Hospital

Enrollment

165 participants

Start Date

Feb 4, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Exploring the ED90 of remimazolam in Drug-induced Sleep Endoscopy in adults at different BMI groups.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria1

  • \. Age 18-65 years old, 2. ASA Ⅰ-Ⅲ level; 3. Sign an informed consent form.

Exclusion Criteria1

  • A history of central nervous system diseases, cognitive disorders, mental disorders, or communication disorders; 2.serious cardiovascular, respiratory, liver or kidney disease; 3.Anticipated need for tracheal intubation or laryngeal mask; 4.Allergic to benzodiazepines and opioids; 5.Those who have taken sedative, analgesic or antidepressant drugs within 24 hours; 6.Abnormal liver and kidney function; 7.Recently participated in other clinical studies.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRemimazolam

Exploring ED90 induced by remimazolam anesthesia in adults of different BMI groups undergoing drug-induced sleep endoscopy


Locations(1)

Tongji Hospital

Wuhan, Hubei, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06333145


Related Trials